BRTX logo

BioRestorative Therapies (BRTX) Company Overview

Profile

Full Name:

BioRestorative Therapies, Inc.

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

December 5, 2012

Indexes:

Not included

Description:

BioRestorative Therapies (BRTX) focuses on developing innovative treatments using stem cell technology. The company aims to improve health and wellness through regenerative medicine, targeting conditions like chronic pain and obesity. BRTX combines scientific research with advanced therapies to enhance patients' quality of life.

Key Details

Price

$1.75

Annual Revenue

$145.80 K(+21.70% YoY)

Annual EPS

-$2.47(+32.33% YoY)

Annual ROE

-102.66%

Beta

1.33

Events Calendar

Earnings

Next earnings date:

N/A

Recent quarterly earnings:

N/A

Recent annual earnings:

N/A
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

Oct 27, 2021

Analyst ratings

Recent major analysts updates

Aug 14, 24 Roth MKM
Buy
Jun 12, 24 Roth MKM
Buy
Aug 14, 23 Roth MKM
Buy
Dec 7, 22 Roth Capital
Buy
Sep 28, 22 Maxim Group
Buy
Dec 1, 21 Roth Capital
Buy

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Market cap

Technical

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Profit

EPS

ROA & ROE

EBIT & EBITDA

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Equity

Liabilities

Debt

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Free CashFlow

CAPEX

Institutional Ownership

FAQ

  • What is the ticker symbol for BioRestorative Therapies?
  • Does BioRestorative Therapies pay dividends?
  • What sector is BioRestorative Therapies in?
  • What industry is BioRestorative Therapies in?
  • What country is BioRestorative Therapies based in?
  • When did BioRestorative Therapies go public?
  • Is BioRestorative Therapies in the S&P 500?
  • Is BioRestorative Therapies in the NASDAQ 100?
  • Is BioRestorative Therapies in the Dow Jones?
  • When does BioRestorative Therapies report earnings?
  • Should I buy BioRestorative Therapies stock now?

What is the ticker symbol for BioRestorative Therapies?

The ticker symbol for BioRestorative Therapies is NASDAQ:BRTX

Does BioRestorative Therapies pay dividends?

No, BioRestorative Therapies does not pay dividends

What sector is BioRestorative Therapies in?

BioRestorative Therapies is in the Healthcare sector

What industry is BioRestorative Therapies in?

BioRestorative Therapies is in the Biotechnology industry

What country is BioRestorative Therapies based in?

BioRestorative Therapies is headquartered in United States

When did BioRestorative Therapies go public?

BioRestorative Therapies's initial public offering (IPO) was on December 5, 2012

Is BioRestorative Therapies in the S&P 500?

No, BioRestorative Therapies is not included in the S&P 500 index

Is BioRestorative Therapies in the NASDAQ 100?

No, BioRestorative Therapies is not included in the NASDAQ 100 index

Is BioRestorative Therapies in the Dow Jones?

No, BioRestorative Therapies is not included in the Dow Jones index

When does BioRestorative Therapies report earnings?

The date for BioRestorative Therapies's next earnings report has not been announced yet

Should I buy BioRestorative Therapies stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions